Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.

Standard

Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. / Wrage, Michaela; Ruosaari, Salla; Eijk, Paul P; Kaifi, Jussuf; Hollmén, Jaakko; Yekebas, Emre F.; Izbicki, Jakob R.; Brakenhoff, Ruud H; Streichert, Thomas; Riethdorf, Sabine; Glatzel, Markus; Ylstra, Bauke; Pantel, Klaus; Wikman, Harriet.

In: CLIN CANCER RES, Vol. 15, No. 5, 5, 2009, p. 1566-1574.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Wrage, M, Ruosaari, S, Eijk, PP, Kaifi, J, Hollmén, J, Yekebas, EF, Izbicki, JR, Brakenhoff, RH, Streichert, T, Riethdorf, S, Glatzel, M, Ylstra, B, Pantel, K & Wikman, H 2009, 'Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.', CLIN CANCER RES, vol. 15, no. 5, 5, pp. 1566-1574. <http://www.ncbi.nlm.nih.gov/pubmed/19208797?dopt=Citation>

APA

Wrage, M., Ruosaari, S., Eijk, P. P., Kaifi, J., Hollmén, J., Yekebas, E. F., Izbicki, J. R., Brakenhoff, R. H., Streichert, T., Riethdorf, S., Glatzel, M., Ylstra, B., Pantel, K., & Wikman, H. (2009). Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. CLIN CANCER RES, 15(5), 1566-1574. [5]. http://www.ncbi.nlm.nih.gov/pubmed/19208797?dopt=Citation

Vancouver

Wrage M, Ruosaari S, Eijk PP, Kaifi J, Hollmén J, Yekebas EF et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. CLIN CANCER RES. 2009;15(5):1566-1574. 5.

Bibtex

@article{33f7fd30f958447fa2f720512c6cd8d5,
title = "Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.",
abstract = "PURPOSE: Bone marrow is a common homing organ for early disseminated tumor cells (DTC) and their presence can predict the subsequent occurrence of overt metastasis and survival in lung cancer. It is still unclear whether the shedding of DTC from the primary tumor is a random process or a selective release driven by a specific genomic pattern. EXPERIMENTAL DESIGN: DTCs were identified in bone marrow from lung cancer patients by an immunocytochemical cytokeratin assay. Genomic aberrations and expression profiles of the respective primary tumors were assessed by microarrays and fluorescence in situ hybridization analyses. The most significant results were validated on an independent set of primary lung tumors and brain metastases. RESULTS: Combination of DNA copy number profiles (array comparative genomic hybridization) with gene expression profiles identified five chromosomal regions differentiating bone marrow-negative from bone marrow-positive patients (4q12-q32, 10p12-p11, 10q21-q22, 17q21, and 20q11-q13). Copy number changes of 4q12-q32 were the most prominent finding, containing the highest number of differentially expressed genes irrespective of chromosomal size (P=0.018). Fluorescence in situ hybridization analyses on further primary lung tumor samples confirmed the association between loss of 4q and bone marrow-positive status. In bone marrow-positive patients, 4q was frequently lost (37% versus 7%), whereas gains could be commonly found among bone marrow-negative patients (7% versus 17%). The same loss was also found to be common in brain metastases from both small and non-small cell lung cancer patients (39%). CONCLUSIONS: Thus, our data indicate, for the first time, that early hematogenous dissemination of tumor cells might be driven by a specific pattern of genomic changes.",
author = "Michaela Wrage and Salla Ruosaari and Eijk, {Paul P} and Jussuf Kaifi and Jaakko Hollm{\'e}n and Yekebas, {Emre F.} and Izbicki, {Jakob R.} and Brakenhoff, {Ruud H} and Thomas Streichert and Sabine Riethdorf and Markus Glatzel and Bauke Ylstra and Klaus Pantel and Harriet Wikman",
year = "2009",
language = "Deutsch",
volume = "15",
pages = "1566--1574",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.

AU - Wrage, Michaela

AU - Ruosaari, Salla

AU - Eijk, Paul P

AU - Kaifi, Jussuf

AU - Hollmén, Jaakko

AU - Yekebas, Emre F.

AU - Izbicki, Jakob R.

AU - Brakenhoff, Ruud H

AU - Streichert, Thomas

AU - Riethdorf, Sabine

AU - Glatzel, Markus

AU - Ylstra, Bauke

AU - Pantel, Klaus

AU - Wikman, Harriet

PY - 2009

Y1 - 2009

N2 - PURPOSE: Bone marrow is a common homing organ for early disseminated tumor cells (DTC) and their presence can predict the subsequent occurrence of overt metastasis and survival in lung cancer. It is still unclear whether the shedding of DTC from the primary tumor is a random process or a selective release driven by a specific genomic pattern. EXPERIMENTAL DESIGN: DTCs were identified in bone marrow from lung cancer patients by an immunocytochemical cytokeratin assay. Genomic aberrations and expression profiles of the respective primary tumors were assessed by microarrays and fluorescence in situ hybridization analyses. The most significant results were validated on an independent set of primary lung tumors and brain metastases. RESULTS: Combination of DNA copy number profiles (array comparative genomic hybridization) with gene expression profiles identified five chromosomal regions differentiating bone marrow-negative from bone marrow-positive patients (4q12-q32, 10p12-p11, 10q21-q22, 17q21, and 20q11-q13). Copy number changes of 4q12-q32 were the most prominent finding, containing the highest number of differentially expressed genes irrespective of chromosomal size (P=0.018). Fluorescence in situ hybridization analyses on further primary lung tumor samples confirmed the association between loss of 4q and bone marrow-positive status. In bone marrow-positive patients, 4q was frequently lost (37% versus 7%), whereas gains could be commonly found among bone marrow-negative patients (7% versus 17%). The same loss was also found to be common in brain metastases from both small and non-small cell lung cancer patients (39%). CONCLUSIONS: Thus, our data indicate, for the first time, that early hematogenous dissemination of tumor cells might be driven by a specific pattern of genomic changes.

AB - PURPOSE: Bone marrow is a common homing organ for early disseminated tumor cells (DTC) and their presence can predict the subsequent occurrence of overt metastasis and survival in lung cancer. It is still unclear whether the shedding of DTC from the primary tumor is a random process or a selective release driven by a specific genomic pattern. EXPERIMENTAL DESIGN: DTCs were identified in bone marrow from lung cancer patients by an immunocytochemical cytokeratin assay. Genomic aberrations and expression profiles of the respective primary tumors were assessed by microarrays and fluorescence in situ hybridization analyses. The most significant results were validated on an independent set of primary lung tumors and brain metastases. RESULTS: Combination of DNA copy number profiles (array comparative genomic hybridization) with gene expression profiles identified five chromosomal regions differentiating bone marrow-negative from bone marrow-positive patients (4q12-q32, 10p12-p11, 10q21-q22, 17q21, and 20q11-q13). Copy number changes of 4q12-q32 were the most prominent finding, containing the highest number of differentially expressed genes irrespective of chromosomal size (P=0.018). Fluorescence in situ hybridization analyses on further primary lung tumor samples confirmed the association between loss of 4q and bone marrow-positive status. In bone marrow-positive patients, 4q was frequently lost (37% versus 7%), whereas gains could be commonly found among bone marrow-negative patients (7% versus 17%). The same loss was also found to be common in brain metastases from both small and non-small cell lung cancer patients (39%). CONCLUSIONS: Thus, our data indicate, for the first time, that early hematogenous dissemination of tumor cells might be driven by a specific pattern of genomic changes.

M3 - SCORING: Zeitschriftenaufsatz

VL - 15

SP - 1566

EP - 1574

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 5

M1 - 5

ER -